Back to List View Graph View

Bruton tyrosine kinase (BTK)

Bruton agammaglobulinemia tyrosine kinase (BTK) is a non-receptor tyrosine kinase that plays an essential and non-redundant role in B-cell development, maturation, and signaling.

Where the papers sit

21 papers from the last 6 months study Bruton tyrosine kinase (BTK) directly · updated from PubMed 15 Nov 2026

Those 21 are all about one subject.

  • BTK-Targeted Therapeutics

    BTK therapy is expanding beyond first-generation covalent inhibitors toward noncovalent agents and targeted degraders. Clinical work emphasizes pharmacokinetics, dose modification, real-world outcomes, and efficacy in CLL, DLBCL, PCNSL, and other hematologic malignancies. Preclinical studies are optimizing selectivity, oral exposure, resistance profiles, and platelet-sparing antithrombotic effects. The field is moving toward safer, more durable BTK control while testing activity across broader immune and inflammatory diseases.

    21 papers

PARADIGM SHIFT

BTK is a therapeutic signaling node beyond malignant B cells

The platelet thrombosis model studying NX-2127 and NX-5948 and the Japanese encephalitis virus-infected mouse model studying zinc supplementation both depart from the malignancy-centered assumption that BTK is chiefly a B-cell therapeutic target. In platelets, selective BTK degradation reduced thrombosis without impairing haemostasis, while in macrophages, zinc-mediated inhibition of BTK phosphorylation reduced neuroinflammation and neuronal injury. Together, these findings extend BTK-directed intervention to distinct nonmalignant processes—thrombus formation and virus-induced CNS inflammation—and suggest that cell-specific BTK modulation, rather than generalized inhibition in B-cell disease, is a broader therapeutic strategy 42379226Jun 42340066Jun.

Papers

The 21 papers from the last 6 months that study Bruton tyrosine kinase (BTK) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BTK-Targeted Therapeutics (21)
  1. Emerging drug profile: bexobrutideg. Leukemia & lymphoma · 12 Oct 2026 PMID 42860822
  2. Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786239
  3. Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. Cancer · 15 Sept 2026 PMID 42740716
  4. Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720469
  5. Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. Clinical and translational science · 2 Sept 2026 PMID 42682178
  6. Discovery of novel acridine based inhibitors of Bruton's tyrosine kinase (BTK) via pharmacophore modeling and machine learning-driven virtual screening followed by molecular dynamic studies. Journal of computer-aided molecular design · 1 Sept 2026 PMID 42678624
  7. Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies. European journal of medicinal chemistry · 7 Aug 2026 PMID 42566884
  8. Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. Advances in therapy · 24 Jul 2026 PMID 42496861
  9. Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 1 Jul 2026 PMID 42385585
  10. Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis. Blood advances · 30 Jun 2026 PMID 42379226
  11. BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules? Blood cancer discovery · 26 Jun 2026 PMID 42360198
  12. Zinc Inhibits BTK Phosphorylation in Macrophages to Ameliorate Encephalitis in Neurotropic Virus-Infected Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 24 Jun 2026 PMID 42340066
  13. Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. Oncology and therapy · 22 Jun 2026 PMID 42329588
  14. A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART). Japanese journal of clinical oncology · 18 Jun 2026 PMID 42315131
  15. BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability. Journal of hematology & oncology · 18 Jun 2026 PMID 42310786
  16. Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 15 Jun 2026 PMID 42297099
  17. PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. Blood advances · 9 Jun 2026 PMID 42263669
  18. Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. Journal of hematology & oncology · 7 Jun 2026 PMID 42252468
  19. Common biomarkers of Alzheimer disease and postoperative delirium. Medicine · 30 May 2026 PMID 42216384
  20. Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. Journal of neuro-oncology · 29 May 2026 PMID 42213292
  21. QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 May 2026 PMID 42184887

By study type

Clinical trials (4)
  1. Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786239
  2. Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. Advances in therapy · 24 Jul 2026 PMID 42496861
  3. A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART). Japanese journal of clinical oncology · 18 Jun 2026 PMID 42315131
  4. Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 15 Jun 2026 PMID 42297099
Observational studies and case reports (3)
  1. Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. Cancer · 15 Sept 2026 PMID 42740716
  2. Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 1 Jul 2026 PMID 42385585
  3. Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. Journal of neuro-oncology · 29 May 2026 PMID 42213292
Human data, design not indexed (2)
  1. PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. Blood advances · 9 Jun 2026 PMID 42263669
  2. Common biomarkers of Alzheimer disease and postoperative delirium. Medicine · 30 May 2026 PMID 42216384
Preclinical: animal, cell and lab studies (7)
  1. Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720469
  2. Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. Clinical and translational science · 2 Sept 2026 PMID 42682178
  3. Discovery of novel acridine based inhibitors of Bruton's tyrosine kinase (BTK) via pharmacophore modeling and machine learning-driven virtual screening followed by molecular dynamic studies. Journal of computer-aided molecular design · 1 Sept 2026 PMID 42678624
  4. Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies. European journal of medicinal chemistry · 7 Aug 2026 PMID 42566884
  5. Zinc Inhibits BTK Phosphorylation in Macrophages to Ameliorate Encephalitis in Neurotropic Virus-Infected Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 24 Jun 2026 PMID 42340066
  6. BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability. Journal of hematology & oncology · 18 Jun 2026 PMID 42310786
  7. QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 May 2026 PMID 42184887
Unclassified: not yet indexed with MeSH (5)
  1. Emerging drug profile: bexobrutideg. Leukemia & lymphoma · 12 Oct 2026 PMID 42860822
  2. Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis. Blood advances · 30 Jun 2026 PMID 42379226
  3. BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules? Blood cancer discovery · 26 Jun 2026 PMID 42360198
  4. Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. Oncology and therapy · 22 Jun 2026 PMID 42329588
  5. Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. Journal of hematology & oncology · 7 Jun 2026 PMID 42252468